$250K
+$250K this year1 filing since 2026 · latest Options filed
Bascule Biosciences is a development-led oncology company that acquires induced-proximity programs at the stage when development decisions are most consequential. The company, founded in 2026 and based in New Rochelle, New York, is operating largely in stealth. It is engaging the targeted protein degradation community, including a planned presence at the 9th TPD Summit in Boston in October 2026.
What sets it apart
A development-led model that acquires induced-proximity oncology programs at the point where development decisions are most consequential, rather than originating discovery-stage assets.
A portfolio of acquired induced-proximity programs in oncology that the company advances through development.
